The GLP-1 Frontier: Why Retatrutide (LY3437943) is the Next Generation of Triple Agonism
The landscape of metabolic research is witnessing a seismic shift. While the scientific community is still integrating the success of Semaglutide (GLP-1) and Tirzepatide (GLP-1/GIP), a new molecule—Retatrutide (LY3437943)—is setting a new pharmacological benchmark. As research transitions from dual-agonism to Triple-Agonism, understanding the multi-receptor synergy of Retatrutide is essential for any advanced laboratory study. 1. […]
The GLP-1 Frontier: Why Retatrutide (LY3437943) is the Next Generation of Triple Agonism Read More »